VCG
NKTR icon

Vantage Consulting Group’s Nektar Therapeutics NKTR Stock Holding History

Vantage Consulting Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,738
Closed -$18.3K – 231
2023
Q1 		$18.3K Buy
1,738
+955
+122% +$28.9K 0.01% 231
2022
Q4 		$26.6K Buy
+783
New +$37.9K 0.02% 211
2022
Q3 		– Sell
-712
Closed -$41K – 219
2022
Q2 		$41K Buy
+712
New +$44.9K 0.02% 212
2021
Q1 		– Sell
-73
Closed -$19K – 1049
2020
Q4 		$19K Buy
+73
New +$18.9K ﹤0.01% 901

Other funds holding NKTR

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Vantage Consulting Group's NKTR Position: Q2 2023 in Review

Vantage Consulting Group sold out of Nektar Therapeutics (NKTR) in Q2 2023, closing a stake of 1,738 shares — an estimated $18.3K sold.

Vantage Consulting Group first reported a position in NKTR in Q4 2020 and held it in 4 quarters. The position peaked at $41K in Q2 2022. 146 funds tracked by Wall St. Rank hold NKTR as of Q2 2023.

  • Vantage Consulting Group reported no remaining Nektar Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Vantage Consulting Group sold 1,738 Nektar Therapeutics shares in Q2 2023, an estimated $18.3K.
  • Vantage Consulting Group first reported a position in Nektar Therapeutics in Q4 2020 and held it in 4 quarters.
  • Vantage Consulting Group's Nektar Therapeutics position peaked at $41K in Q2 2022.
  • 146 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2023.

Based on Vantage Consulting Group's 13F filing for Q2 2023, filed 11 Aug 2023.